Stacy Parker Byone
Nurse Practitioner · Long Beach, CANPI 1124202361
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Seagen Inc. at 51.0% of the total. Reporting peaked in 2023 at $26,331 and has fallen 62.3% since, to $9,932 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 281 payments — averaging $171.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$25K
- Pfizer$14K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$1K
- Merck$994
- Genentech USA, Inc.$516
- plus $5K from 36 others
Across 7 payments — averaging $225.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$3,7138%
- Speaking & faculty fees$21,85545%
- Travel & lodging$10,78122%
- Food & beverage$11,56824%
- Education$3131%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,230 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 58 | $919,733 |
| Lenalidomide | 52 | $751,264 |
| RevlimidLenalidomide | 32 | $677,252 |
| IclusigPonatinib Hcl | 11 | $406,891 |
| PomalystPomalidomide | 14 | $400,104 |
| LorbrenaLorlatinib | 18 | $354,955 |
| TabrectaCapmatinib Hydrochloride | 13 | $276,039 |
| AlecensaAlectinib Hcl | 12 | $208,540 |
| JakafiRuxolitinib Phosphate | 13 | $180,007 |
| UdenycaPegfilgrastim-Cbqv | 11 | $42,056 |
| XareltoRivaroxaban | 16 | $17,293 |
| EliquisApixaban | 19 | $12,029 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 44 | $835 |
| Fentanyl | 14 | $730 |
| Acyclovir | 43 | $517 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $488 | $919,73358 claims |
| Bristol Myers SquibbRevlimid | $222 | $677,25232 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig | $125 | $406,89111 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,952 | $400,10414 claims |
| PfizerLorbrena, Eliquis | $13,597 | $366,98437 claims |
| NovartisTabrecta | $55 | $276,03913 claims |
| Genentech USA, Inc.Alecensa | $516 | $208,54012 claims |
| Incyte CorporationJakafi | $467 | $180,00713 claims |
| Johnson & JohnsonXarelto | $1,273 | $17,29316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Long Beach
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.